perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”10.21508/1027-4065-2021-66-2-41-48perinatology-1372Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSПрогностическая ценность биомаркеров сердечной недостаточности в оценке кардиальной дисфункции у плода и новорожденногоPrognostic value of heart failure biomarkers in the assessment of cardiac dysfunction in the fetus and newbornhttps://orcid.org/0000-0003-2035-5653СавченкоО. А.SavchenkoO. A.

Савченко Ольга Анатольевна – к.м.н., асс. кафедры госпитальной педиатрии Омского государственного медицинского университета644099 г. Омск, ул. Ленина, д. 12 

Omsk

olgasav1978@mail.ruhttps://orcid.org/0000-0002-6444-1871ПавлиноваЕ. Б.PavlinovaE. B.

Павлинова Елена Борисовна – д.м.н., доц., зав. кафедрой госпитальной педиатрии Омского государственного медицинского университета644099 г. Омск, ул. Ленина, д. 12 

Omsk

https://orcid.org/0000-0002-8555-8761ПолянскаяН. А.PolyanskayaN. A.

Полянская Наталья Александровна – к.м.н., доц. кафедры госпитальной педиатрии Омского государственного медицинского университета644099 г. Омск, ул. Ленина, д. 12 

Omsk

https://orcid.org/0000-0002-3081-4676КиршинаИ. А.KirshinaI. A.

Киршина Ирина Алексеевна – к.м.н., асс. кафедры госпитальной педиатрии Омского государственного медицинского университета644099 г. Омск, ул. Ленина, д. 12 

Omsk

https://orcid.org/0000-0002-5446-2126ГубичА. А.GubichA. A.

Губич Анастасия Андреевна – аспирант, асс. кафедры госпитальной педиатрии Омского государственного медицинского университета644099 г. Омск, ул. Ленина, д. 12 

Omsk

ЧуприкЮ. В.ChuprikYu. V.

Чуприк Юлия Владимировна – врач высшей категории, зав. отделением лучевой диагностики – врач ультразвуковой диагностики Городского клинического перинатального центра644007 г. Омск, ул. Герцена, д. 69

Omsk

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical UniversityRussian FederationБУЗОО «Городской клинический перинатальный центр»РоссияCity Clinical Perinatal CenterRussian Federation2021180520216624148Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20212021Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/1372

Одна из важнейших задач современной перинатологии – оценка функции сердца плода и гемодинамическая стабилизация новорожденного ребенка в постнатальном периоде. Понимание патофизиологических механизмов, лежащих в основе дисфункции миокарда как у плода, так и у новорожденного, позволит разработать превентивные мероприятия и изменить терапевтический подход к данной категории детей. В обзоре освещены вопросы нарушения механизмов взаиморегуляции сердца плода и плаценты, а также представлены диагностические возможности применения в медицине плода и новорожденного современных биомаркеров дисфункции сердечно-сосудистой системы – тропонинов, N-концевого предшественника мозгового натрийуретического пептида и растворимого супрессора онкогенности 2-го типа.

The assessment of the cardiac function of the fetus and hemodynamic stabilization of the newborn in the postnatal period is one of the most important tasks of modern perinatology. Understanding the pathophysiological mechanisms, the basis of the myocardial dysfunction in both the fetus and the newborn, can help to develop preventive measures and change the therapeutic approach to this category of children. This review highlights the problems of the disruption of the mechanisms of interregulation in the fetal heart and placenta, as well as the diagnostic possibilities of modern biomarkers of cardiovascular dysfunction – troponins, N-terminal precursor of brain natriuretic peptide and soluble type 2 tumor suppressor – in fetal and newborn.

плодноворожденныйгемодинамикасердечная недостаточностьбиомаркерыfetalnewbornhemodynamicsheart failurebiomarkersReferencesBurton G.J., Jauniaux E. Development of the Human Placenta and Fetal Heart: Synergic or Independent? Front Physiol 2018; 9: 373. DOI: 10.3389/fphys.2018.00373Burton G.J., Jauniaux E. Development of the Human Placenta and Fetal Heart: Synergic or Independent? Front Physiol 2018; 9: 373. DOI: 10.3389/fphys.2018.00373Linask K.K. The heart-placenta axis in the first month of pregnancy: induction and prevention of cardiovascular birth defects. J Pregnancy 2013; 2013:320413. DOI: 10.1155/2013/320413Linask K.K. The heart-placenta axis in the first month of pregnancy: induction and prevention of cardiovascular birth defects. J Pregnancy 2013; 2013:320413. DOI: 10.1155/2013/320413Midgett M., Thornburg K., Rugonyi S. Blood flow patterns underlie developmental heart defects. Am J Physiol Heart Circ Physiol 2017; 312(3): 632–642. DOI: 10.1152/ajpheart.00641.2016Midgett M., Thornburg K., Rugonyi S. Blood flow patterns underlie developmental heart defects. Am J Physiol Heart Circ Physiol 2017; 312(3): 632–642. DOI: 10.1152/ajpheart.00641.2016Hamill N., Romero R., Hassan S., Lee W., Myers S.A., Mittal P. The fetal cardiovascular response to increased placental vascular impedance to flow determined with 4-dimensional ultrasound using spatiotemporal image correlation and virtual organ computer-aided analysis. Am J Obstet Gynecol 2013; 208(2): 153.e1–13. DOI: 10.1016/j.ajog.2012.11.043Hamill N., Romero R., Hassan S., Lee W., Myers S.A., Mittal P. The fetal cardiovascular response to increased placental vascular impedance to flow determined with 4-dimensional ultrasound using spatiotemporal image correlation and virtual organ computer-aided analysis. Am J Obstet Gynecol 2013; 208(2): 153.e1–13. DOI: 10.1016/j.ajog.2012.11.043Burton G.J., Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am J Obstet Gynecol 2018; 218(2S): 745–761. DOI: 10.1016/j.ajog.2017.11.577Burton G.J., Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am J Obstet Gynecol 2018; 218(2S): 745–761. DOI: 10.1016/j.ajog.2017.11.577Toyoshima K., Kawataki M., Ohyama M., Shibasaki J., Yamaguchi N., Hoshino R. Tailor-made circulatory management based on the stress-velocity relationship in preterm infants. J Formos Med Assoc 2013; 112(9): 510–517. DOI: 10.1016/j.jfma.2013.02.011Toyoshima K., Kawataki M., Ohyama M., Shibasaki J., Yamaguchi N., Hoshino R. Tailor-made circulatory management based on the stress-velocity relationship in preterm infants. J Formos Med Assoc 2013; 112(9): 510–517. DOI: 10.1016/j.jfma.2013.02.011Giussani D.A., Camm E.J., Niu Y., Richter H.G., Blanco C.E., Gottschalk R., Blake E.Z. Developmental programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress. PLoS One 2012; 7(2): e31017. DOI: 10.1371/journal.pone.0031017Giussani D.A., Camm E.J., Niu Y., Richter H.G., Blanco C.E., Gottschalk R., Blake E.Z. Developmental programming of cardiovascular dysfunction by prenatal hypoxia and oxidative stress. PLoS One 2012; 7(2): e31017. DOI: 10.1371/journal.pone.0031017Botting K.J., Skeffington K.L., Niu Y., Allison B.J., Brain K.L., Itani N. Translatable mitochondria-targeted protection against programmed cardiovascular dysfunction. Sci Adv 2020; 6(34): eabb1929. DOI: 10.1126/sciadv.abb1929Botting K.J., Skeffington K.L., Niu Y., Allison B.J., Brain K.L., Itani N. Translatable mitochondria-targeted protection against programmed cardiovascular dysfunction. Sci Adv 2020; 6(34): eabb1929. DOI: 10.1126/sciadv.abb1929Armstrong K., Franklin O., Sweetman D., Molloy E.J. Cardiovascular dysfunction in infants with neonatal encephalopathy. Arch DisChild 2012; 97(4): 372–5. DOI: 10.1136/adc.2011.214205Armstrong K., Franklin O., Sweetman D., Molloy E.J. Cardiovascular dysfunction in infants with neonatal encephalopathy. Arch DisChild 2012; 97(4): 372–5. DOI: 10.1136/adc.2011.214205Giesinger R.E., Bailey L.J., Deshpande P., McNamara P.J. Hypoxic-Ischemic Encephalopathy and Therapeutic Hypothermia: The Hemodynamic Perspective. J Pediatr 2017; 180: 22–30. DOI: 10.1016/j.jpeds.2016.09.009Giesinger R.E., Bailey L.J., Deshpande P., McNamara P.J. Hypoxic-Ischemic Encephalopathy and Therapeutic Hypothermia: The Hemodynamic Perspective. J Pediatr 2017; 180: 22–30. DOI: 10.1016/j.jpeds.2016.09.009Levy P.T., Tissot C., Horsberg Eriksen B., Nestaas E., Rogerson S., McNamara P.J. European Special Interest Group ‘Neonatologist Performed Echocardiography’ (NPE). Application of Neonatologist Performed Echocardiography in the Assessment and Management of Neonatal Heart Failure unrelated to Congenital Heart Disease. Pediatr Res 2018; 84(1): 78–88. DOI: 10.1038/s41390-018-0075-zLevy P.T., Tissot C., Horsberg Eriksen B., Nestaas E., Rogerson S., McNamara P.J. European Special Interest Group ‘Neonatologist Performed Echocardiography’ (NPE). Application of Neonatologist Performed Echocardiography in the Assessment and Management of Neonatal Heart Failure unrelated to Congenital Heart Disease. Pediatr Res 2018; 84(1): 78–88. DOI: 10.1038/s41390-018-0075-zКирьяков К.С., Хатагова Р.Б., Тризна Е.В., Зеленина З.А., Яковлев А.В., Петрова Н.А. Коррекция кислотно-основного состояния при гипоксически-ишемическом поражении головного мозга у новорожденных. Российский вестник перинатологии и педиатрии 2018; 63(1): 40–45. [Kiriakov K.S., Khatagova R.B., Trizna E.V., Zelenina Z.A., Jakovlev A.V., Petrova N.A. Correction of the acid-base balance in the presence of the hypoxic-ischemic brain damage in newborns. Rossiyskiy Vestnik Perinatologii i pediatrii 2018; 63(1): 40–45. (in Russ.)] DOI: 10.21508/1027-4065-2018-63-1-40-45Кирьяков К.С., Хатагова Р.Б., Тризна Е.В., Зеленина З.А., Яковлев А.В., Петрова Н.А. Коррекция кислотно-основного состояния при гипоксически-ишемическом поражении головного мозга у новорожденных. Российский вестник перинатологии и педиатрии 2018; 63(1): 40–45. [Kiriakov K.S., Khatagova R.B., Trizna E.V., Zelenina Z.A., Jakovlev A.V., Petrova N.A. Correction of the acid-base balance in the presence of the hypoxic-ischemic brain damage in newborns. Rossiyskiy Vestnik Perinatologii i pediatrii 2018; 63(1): 40–45. (in Russ.)] DOI: 10.21508/1027-4065-2018-63-1-40-45Tapia-Rombo C.A., Carpio-Hernández J.C., Sala- zar-Acuña A.H., Alvarez-Vázquez E., Mendoza-Zanella R.M. Detection of transitory myocardial ischemia secondary to perinatal asphyxia. Arch Med Res 2000; 31(4): 377–383. DOI: 10.1016/s0188-4409(00)00088-6Tapia-Rombo C.A., Carpio-Hernández J.C., Sala- zar-Acuña A.H., Alvarez-Vázquez E., Mendoza-Zanella R.M. Detection of transitory myocardial ischemia secondary to perinatal asphyxia. Arch Med Res 2000; 31(4): 377–383. DOI: 10.1016/s0188-4409(00)00088-6Robertson N.J., Faulkner S., Fleiss B., Bainbridge A., Andorka C., Price D. Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain 2013; 136(1): 90–105. DOI: 10.1093/brain/aws285Robertson N.J., Faulkner S., Fleiss B., Bainbridge A., Andorka C., Price D. Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain 2013; 136(1): 90–105. DOI: 10.1093/brain/aws285Liu J.Q., Lee T.F., Bigam D.L., Cheung P.Y. Effects of post-resuscitation treatment with N-acetylcysteine on cardiac recovery in hypoxic newborn piglets. PLoS One 2010; 5(12): 15322. DOI: 10.1371/journal.pone.0015322Liu J.Q., Lee T.F., Bigam D.L., Cheung P.Y. Effects of post-resuscitation treatment with N-acetylcysteine on cardiac recovery in hypoxic newborn piglets. PLoS One 2010; 5(12): 15322. DOI: 10.1371/journal.pone.0015322Santhanakrishnan R., Chong J.P., Ng T.P., Ling L.H., Sim D., Leong K.T. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012; 14(12): 1338–47. DOI: 10.1093/eurjhf/hfs130Santhanakrishnan R., Chong J.P., Ng T.P., Ling L.H., Sim D., Leong K.T. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 2012; 14(12): 1338–47. DOI: 10.1093/eurjhf/hfs130Jhund P.S., Claggett B.L., Voors A.A., Zile M.R., Packer M., Pieske B.M. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail 2014; 7(6): 953–959. DOI: 0.1161/CIRCHEARTFAILURE.114.001427Jhund P.S., Claggett B.L., Voors A.A., Zile M.R., Packer M., Pieske B.M. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circ Heart Fail 2014; 7(6): 953–959. DOI: 0.1161/CIRCHEARTFAILURE.114.001427Sternberg M., Pasini E., Chen-Scarabelli C., Corsetti G., Patel H., Linardi D. Elevated Cardiac Troponin in Clinical Scenarios Beyond Obstructive Coronary Artery Disease. Med Sci Monit 2019; 25: 7115–7125. DOI: 10.12659/MSM.915830Sternberg M., Pasini E., Chen-Scarabelli C., Corsetti G., Patel H., Linardi D. Elevated Cardiac Troponin in Clinical Scenarios Beyond Obstructive Coronary Artery Disease. Med Sci Monit 2019; 25: 7115–7125. DOI: 10.12659/MSM.915830Kajioka S., Takahashi-Yanaga F., Shahab N., Onimaru M., Matsuda M., Takahashi R. Endogenous cardiac troponin T modulates Ca(2+)-mediated smooth muscle contraction. Sci Rep 2012; 2: 979. DOI: 10.1038/srep00979Kajioka S., Takahashi-Yanaga F., Shahab N., Onimaru M., Matsuda M., Takahashi R. Endogenous cardiac troponin T modulates Ca(2+)-mediated smooth muscle contraction. Sci Rep 2012; 2: 979. DOI: 10.1038/srep00979Tarkowska A., Furmaga-Jabłońska W. The Evaluation of Cardiac Troponin T in Newborns. Biomed Hub 2017; 2(3): 1–7. DOI: 10.1159/000481086Tarkowska A., Furmaga-Jabłońska W. The Evaluation of Cardiac Troponin T in Newborns. Biomed Hub 2017; 2(3): 1–7. DOI: 10.1159/000481086Pan B., Xu Z.W., Xu Y., Liu L.J., Zhu J., Wang X. Diastolic dysfunction and cardiac troponin I decrease in aging hearts. Arch Biochem Biophys 2016; 603: 20–8. DOI: 10.1016/j.abb.2016.05.008Pan B., Xu Z.W., Xu Y., Liu L.J., Zhu J., Wang X. Diastolic dysfunction and cardiac troponin I decrease in aging hearts. Arch Biochem Biophys 2016; 603: 20–8. DOI: 10.1016/j.abb.2016.05.008Li Y., Zhang L., Jean-Charles P.Y., Nan C., Chen G., Tian J. Dose-dependent diastolic dysfunction and early death in a mouse model with cardiac troponin mutations. J Mol Cell Cardiol 2013; 62: 227–236. DOI: 10.1016/ j.yjmcc.2013.06.007Li Y., Zhang L., Jean-Charles P.Y., Nan C., Chen G., Tian J. Dose-dependent diastolic dysfunction and early death in a mouse model with cardiac troponin mutations. J Mol Cell Cardiol 2013; 62: 227–236. DOI: 10.1016/ j.yjmcc.2013.06.007Lin X.Q., Zheng L.R. Myocardial ischemic changes of electrocardiogram in intracerebral hemorrhage: A case report and review of literature. World J Clin Cases. 2019; 7(21): 3603– 3614. DOI: 10.12998/wjcc.v7.i21.3603Lin X.Q., Zheng L.R. Myocardial ischemic changes of electrocardiogram in intracerebral hemorrhage: A case report and review of literature. World J Clin Cases. 2019; 7(21): 3603– 3614. DOI: 10.12998/wjcc.v7.i21.3603Neves A.L., Henriques-Coelho T., Leite-Moreira A., Areias J.C. Cardiac injury biomarkers in paediatric age: Are we there yet? Heart Fail Rev 2016; 21(6): 771–781. DOI: 10.1007/s10741-016-9567-2Neves A.L., Henriques-Coelho T., Leite-Moreira A., Areias J.C. Cardiac injury biomarkers in paediatric age: Are we there yet? Heart Fail Rev 2016; 21(6): 771–781. DOI: 10.1007/s10741-016-9567-2Montaldo P., Rosso R., Chello G., Giliberti P. Cardiac troponin I concentrations as a marker of neurodevelopmental outcome at 18 months in newborns with perinatal asphyxia. J Perinatol 2014; 34(4): 292–295. DOI: 10.1038/jp.2014.1Montaldo P., Rosso R., Chello G., Giliberti P. Cardiac troponin I concentrations as a marker of neurodevelopmental outcome at 18 months in newborns with perinatal asphyxia. J Perinatol 2014; 34(4): 292–295. DOI: 10.1038/jp.2014.1Lin D.C., Diamandis E.P., Januzzi J.L. Jr., Maisel A., Jaffe A.S., Clerico A. Natriuretic peptides in heart failure. Clin Chem 2014; 60(8): 1040–1046. DOI: 10.1373/clinchem.2014.223057Lin D.C., Diamandis E.P., Januzzi J.L. Jr., Maisel A., Jaffe A.S., Clerico A. Natriuretic peptides in heart failure. Clin Chem 2014; 60(8): 1040–1046. DOI: 10.1373/clinchem.2014.223057Stebbing P.N., Gude N.M., King R.G., Brennecke S.P. Alpha-atrial natriuretic peptide-induced attenuation of vasoconstriction in the fetal circulation of the human isolated perfused placenta. J Perinat Med 1996; 24(3): 253–60. DOI: 10.1515/jpme.1996.24.3.253Stebbing P.N., Gude N.M., King R.G., Brennecke S.P. Alpha-atrial natriuretic peptide-induced attenuation of vasoconstriction in the fetal circulation of the human isolated perfused placenta. J Perinat Med 1996; 24(3): 253–60. DOI: 10.1515/jpme.1996.24.3.253Cameron V.A., Ellmers L.J. Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinol 2003; 144(6): 2191–2194. DOI: 10.1210/en.2003-0127Cameron V.A., Ellmers L.J. Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinol 2003; 144(6): 2191–2194. DOI: 10.1210/en.2003-0127Baldini P.M., De Vito P., Fraziano M., Mattioli P., Luly P., Di Nardo P. Atrial natriuretic factor inhibits mitogen-induced growth in aortic smooth muscle cells. J Cell Physiol 2002; 193(1): 103–109. DOI: 10.1002/jcp.10155Baldini P.M., De Vito P., Fraziano M., Mattioli P., Luly P., Di Nardo P. Atrial natriuretic factor inhibits mitogen-induced growth in aortic smooth muscle cells. J Cell Physiol 2002; 193(1): 103–109. DOI: 10.1002/jcp.10155Cameron V.A., Ellmers L.J. Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinol 2003; 144(6): 2191–2194. DOI: 10.1210/en.2003-0127Cameron V.A., Ellmers L.J. Minireview: natriuretic peptides during development of the fetal heart and circulation. Endocrinol 2003; 144(6): 2191–2194. DOI: 10.1210/en.2003-0127Nishikimi T., Kuwahara K., Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 2011; 57(2): 131–140. DOI: 10.1016/j.jjcc.2011.01.002Nishikimi T., Kuwahara K., Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 2011; 57(2): 131–140. DOI: 10.1016/j.jjcc.2011.01.002Oremus M., McKelvie R., Don-Wauchope A., Santaguida P.L., Ali U., Balion C. A systematic review of BNP and NT-proB-NP in the management of heart failure: overview and methods. Heart Fail Rev 2014; 19(4): 413–419. DOI: 10.1007/s10741-014-9440-0Oremus M., McKelvie R., Don-Wauchope A., Santaguida P.L., Ali U., Balion C. A systematic review of BNP and NT-proB-NP in the management of heart failure: overview and methods. Heart Fail Rev 2014; 19(4): 413–419. DOI: 10.1007/s10741-014-9440-0Girsen A., Ala-Kopsala M., Mäkikallio K., Vuolteenaho O., Räsänen J. Cardiovascular hemodynamics and umbilical artery N-terminal peptide of proB-type natriuretic peptide in human fetuses with growth restriction. Ultrasound Obstet Gynecol 2007; 29(3): 296–303. DOI: 10.1002/uog.3934Girsen A., Ala-Kopsala M., Mäkikallio K., Vuolteenaho O., Räsänen J. Cardiovascular hemodynamics and umbilical artery N-terminal peptide of proB-type natriuretic peptide in human fetuses with growth restriction. Ultrasound Obstet Gynecol 2007; 29(3): 296–303. DOI: 10.1002/uog.3934Moriichi A., Cho K., Mizushima M., Furuse Y., Akimoto T., Yamada T. B-type natriuretic peptide levels at birth predict cardiac dysfunction in neonates. Pediatr Int 2012; 54(1): 89– 93. DOI: 10.1111/j.1442-200X.2011.03500.xMoriichi A., Cho K., Mizushima M., Furuse Y., Akimoto T., Yamada T. B-type natriuretic peptide levels at birth predict cardiac dysfunction in neonates. Pediatr Int 2012; 54(1): 89– 93. DOI: 10.1111/j.1442-200X.2011.03500.xNadar S.K., Shaikh M.M. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev 2019; 5(1): 50–56. DOI: 10.15420/cfr.2018.27.2Nadar S.K., Shaikh M.M. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev 2019; 5(1): 50–56. DOI: 10.15420/cfr.2018.27.2Kindler A., Seipolt B., Heilmann A., Range U., Rüdiger M., Hofmann S.R. Development of a Diagnostic Clinical Score for Hemodynamically Significant Patent Ductus Arteriosus. Front Pediatr 2017; 5: 280. DOI: 10.3389/fped.2017.00280Kindler A., Seipolt B., Heilmann A., Range U., Rüdiger M., Hofmann S.R. Development of a Diagnostic Clinical Score for Hemodynamically Significant Patent Ductus Arteriosus. Front Pediatr 2017; 5: 280. DOI: 10.3389/fped.2017.00280Tauber K.A., Doyle R., Granina E., Munshi U. B-type natriuretic peptide levels normalise in preterm infants without a patent ductus arteriosus by the fifth postnatal day. Acta Paediatr 2016; 105(8): e352–355. DOI: 10.1111/apa.13480Tauber K.A., Doyle R., Granina E., Munshi U. B-type natriuretic peptide levels normalise in preterm infants without a patent ductus arteriosus by the fifth postnatal day. Acta Paediatr 2016; 105(8): e352–355. DOI: 10.1111/apa.13480Farombi-Oghuvbu I., Matthews T., Mayne P.D., Guerin H., Corcoran J.D. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008; 93(4): 257–260. DOI: 10.1136/adc.2007.120691Farombi-Oghuvbu I., Matthews T., Mayne P.D., Guerin H., Corcoran J.D. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008; 93(4): 257–260. DOI: 10.1136/adc.2007.120691El-Khuffash A., Molloy E. The Use of N-Terminal-Pro-BNP in Preterm Infants. Int J Pediatr 2009; 2009: 175216. DOI: 10.1155/2009/175216El-Khuffash A., Molloy E. The Use of N-Terminal-Pro-BNP in Preterm Infants. Int J Pediatr 2009; 2009: 175216. DOI: 10.1155/2009/175216Farombi-Oghuvbu I., Matthews T., Mayne P.D., Guerin H., Corcoran J.D. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2008; 93(4): F257–260. DOI: 10.1136/adc.2007.120691Farombi-Oghuvbu I., Matthews T., Mayne P.D., Guerin H., Corcoran J.D. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2008; 93(4): F257–260. DOI: 10.1136/adc.2007.120691Leufgen C., Gembruch U., Stoffel-Wagner B., Fimmers R., Merz W.M. N-terminal pro-B-type natriuretic peptide in amniotic fluid of fetuses with known or suspected cardiac load. PLoS One 2017; 12(5): e0177253. DOI: 10.1371/journal.pone.0177253Leufgen C., Gembruch U., Stoffel-Wagner B., Fimmers R., Merz W.M. N-terminal pro-B-type natriuretic peptide in amniotic fluid of fetuses with known or suspected cardiac load. PLoS One 2017; 12(5): e0177253. DOI: 10.1371/journal.pone.0177253Liu Y., Huang Z.L., Gong L., Zhang Z., Zhang S.C., Zhou Y.X. N-terminal pro-brain natriuretic peptide used for screening hemodynamically significant patent ductus arteriosus in very low birth weight infants: How and when? Clin Hemorheol Microcirc 2020; 75(3): 335–347. DOI:10.3233/CH-190803Liu Y., Huang Z.L., Gong L., Zhang Z., Zhang S.C., Zhou Y.X. N-terminal pro-brain natriuretic peptide used for screening hemodynamically significant patent ductus arteriosus in very low birth weight infants: How and when? Clin Hemorheol Microcirc 2020; 75(3): 335–347. DOI:10.3233/CH-190803Tu cu A., Yildirimtürk O., Aytekin S. Diyastolik kalp yetersizli i tanisinda N-terminal B-tipi natriüretik peptidin yeri: Ekokardiyografi bulgulari ile kar ila tirma [The diagnostic value of N-terminal B-type natriuretic peptide in diastolic heart failure: comparison with echocardiographic findings]. Turk Kardiyol Dern Ars 2009; 37(2):112–121. (In Turkish.)Tu cu A., Yildirimtürk O., Aytekin S. Diyastolik kalp yetersizli i tanisinda N-terminal B-tipi natriüretik peptidin yeri: Ekokardiyografi bulgulari ile kar ila tirma [The diagnostic value of N-terminal B-type natriuretic peptide in diastolic heart failure: comparison with echocardiographic findings]. Turk Kardiyol Dern Ars 2009; 37(2):112–121. (In Turkish.)Tschöpe C., Kasner M., Westermann D., Gaub R., Poller W.C., Schultheiss H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005; 26(21): 2277–2284. DOI: 10.1093/eurheartj/ehi406Tschöpe C., Kasner M., Westermann D., Gaub R., Poller W.C., Schultheiss H.P. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005; 26(21): 2277–2284. DOI: 10.1093/eurheartj/ehi406Nadar S.K., Shaikh M.M. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev 2019; 5(1): 50–56. DOI: 10.15420/cfr.2018.27.2Nadar S.K., Shaikh M.M. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev 2019; 5(1): 50–56. DOI: 10.15420/cfr.2018.27.2Pascual-Figal D.A., Januzzi J.L. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 2015; 115(7): 3–7. DOI: 10.1016/j.amjcard.2015.01.034Pascual-Figal D.A., Januzzi J.L. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol 2015; 115(7): 3–7. DOI: 10.1016/j.amjcard.2015.01.034Luo K., Zhang W., Sui L., Li N., Zhang M., Ma X. et al. DIgR1, a novel membrane receptor of the immunoglobulin gene superfamily, is preferentially expressed by antigen-presenting cells. Biochem Biophys Res Commun 2001; 287(1): 35–41. DOI: 10.1006/bbrc.2001.5539Luo K., Zhang W., Sui L., Li N., Zhang M., Ma X. et al. DIgR1, a novel membrane receptor of the immunoglobulin gene superfamily, is preferentially expressed by antigen-presenting cells. Biochem Biophys Res Commun 2001; 287(1): 35–41. DOI: 10.1006/bbrc.2001.5539Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23(5): 479–490. DOI: 10.1016/j.immuni.2005.09.015Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23(5): 479–490. DOI: 10.1016/j.immuni.2005.09.015Jirak P., Mirna M., Wernly B., Paar V., Hoppe U.C., Licht- enauer M. Assessment of Cardiac Remodeling-A Chance for Novel Cardiac Biomarkers? J Clin Med 2020; 9(7): 2087. DOI: 10.3390/jcm9072087Jirak P., Mirna M., Wernly B., Paar V., Hoppe U.C., Licht- enauer M. Assessment of Cardiac Remodeling-A Chance for Novel Cardiac Biomarkers? J Clin Med 2020; 9(7): 2087. DOI: 10.3390/jcm9072087Bayés-Genís A., Núñez J., Lupón J. Soluble ST2 for Prognosis and Monitoring in Heart Failure: The New Gold Standard? J Am Coll Cardiol 2017; 70(19): 2389–2392. DOI: 10.1016/j.jacc.2017.09.031Bayés-Genís A., Núñez J., Lupón J. Soluble ST2 for Prognosis and Monitoring in Heart Failure: The New Gold Standard? J Am Coll Cardiol 2017; 70(19): 2389–2392. DOI: 10.1016/j.jacc.2017.09.031Zach V., Bähr F.L., Edelmann F. Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. Card Fail Rev 2020; 6: 1–7. DOI: 10.15420/cfr.2019.10Zach V., Bähr F.L., Edelmann F. Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. Card Fail Rev 2020; 6: 1–7. DOI: 10.15420/cfr.2019.10Bartunek J., Delrue L., Van Durme F., Muller O., Casselman F., De Wiest B. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008; 52(25): 2166–2174. DOI: 10.1016/j.jacc.2008.09.027Bartunek J., Delrue L., Van Durme F., Muller O., Casselman F., De Wiest B. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008; 52(25): 2166–2174. DOI: 10.1016/j.jacc.2008.09.027Broch K., Andreassen A.K., Ueland T., Michelsen A.E., Stueflotten W., Aukrust P. Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure. Int J Cardiol 2015; 179: 378–384. DOI: 10.1016/j.ijcard.2014.11.003Broch K., Andreassen A.K., Ueland T., Michelsen A.E., Stueflotten W., Aukrust P. Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure. Int J Cardiol 2015; 179: 378–384. DOI: 10.1016/j.ijcard.2014.11.003Greenway S.C. The Continuation of Trickle-Down Medicine: Soluble Suppression of Tumorigenicity-2 (sST2) in Pediatric Heart Failure. Can J Cardiol 2019; 35(6): 692–693. DOI: 10.1016/j.cjca.2019.02.025Greenway S.C. The Continuation of Trickle-Down Medicine: Soluble Suppression of Tumorigenicity-2 (sST2) in Pediatric Heart Failure. Can J Cardiol 2019; 35(6): 692–693. DOI: 10.1016/j.cjca.2019.02.025You H., Jiang W., Jiao M., Wang X., Jia L., You S. Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy. Can J Cardiol 2019; 35(6): 727–735. DOI: 10.1016/j.cjca.2019.02.016You H., Jiang W., Jiao M., Wang X., Jia L., You S. Association of Soluble ST2 Serum Levels With Outcomes in Pediatric Dilated Cardiomyopathy. Can J Cardiol 2019; 35(6): 727–735. DOI: 10.1016/j.cjca.2019.02.016Hoogerwerf J.J., Tanck M.W., van Zoelen M.A., Wittebole X., Laterre P.F., van der Poll T. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010; 36(4): 630–637. DOI: 10.1007/s00134-010-1773-0.Hoogerwerf J.J., Tanck M.W., van Zoelen M.A., Wittebole X., Laterre P.F., van der Poll T. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med 2010; 36(4): 630–637. DOI: 10.1007/s00134-010-1773-0.Stampalija T., Romero R., Korzeniewski S.J., Chaemsaithong P., Miranda J., Yeo L. Soluble ST2 in the fetal inflammatory response syndrome: in vivo evidence of activation of the antiinflammatory limb of the immune response. J Matern Fetal Neonatal Med 2013; 26(14): 1384–1393. DOI: 10.3109/14767058.2013.784258.Stampalija T., Romero R., Korzeniewski S.J., Chaemsaithong P., Miranda J., Yeo L. Soluble ST2 in the fetal inflammatory response syndrome: in vivo evidence of activation of the antiinflammatory limb of the immune response. J Matern Fetal Neonatal Med 2013; 26(14): 1384–1393. DOI: 10.3109/14767058.2013.784258.Romero R., Chaemsaithong P., Tarca A.L., Korzeniewski S.J., Maymon E., Pacora P. Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia – a longitudinal study. J Matern Fetal Neonatal Med 2018; 31(4): 418–432. DOI: 10.1080/14767058.2017.1286319Romero R., Chaemsaithong P., Tarca A.L., Korzeniewski S.J., Maymon E., Pacora P. Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia – a longitudinal study. J Matern Fetal Neonatal Med 2018; 31(4): 418–432. DOI: 10.1080/14767058.2017.1286319Meeusen J.W., Johnson J.N., Gray A., Wendt P., Jefferies J.L., Jaffe A.S. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem 2015; 48(18): 1337– 1340. DOI: 10.1016/j.clinbiochem.2015.08.007Meeusen J.W., Johnson J.N., Gray A., Wendt P., Jefferies J.L., Jaffe A.S. Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clin Biochem 2015; 48(18): 1337– 1340. DOI: 10.1016/j.clinbiochem.2015.08.007

The authors declare that there are no conflicts of interest present.